A Phase IIb, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Mild-Moderate ARDS
This is phase IIb, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 of one dose 10^10 exosome particles, to Prevent Clinical Deterioration in Patients with Mild-Moderate ARDS
100 项与 Nano24 Ltd. 相关的临床结果
0 项与 Nano24 Ltd. 相关的专利(医药)
100 项与 Nano24 Ltd. 相关的药物交易
100 项与 Nano24 Ltd. 相关的转化医学